BriaCell Therapeutics Corporation
BriaCell is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies to transform cancer care. Their lead candidate, Bria-IMT™, is a patented, off-the-shelf, cell-based immunotherapy for metastatic breast cancer, which has received FDA Fast Track status and is in a pivotal Phase 3 study. They also develop Bria-OTS™, a personalized off-the-shelf immunotherapy platform, which is being evaluated in clinical trials for various cancers including breast and prostate cancer. BriaCell's technology aims to activate the immune system to specifically target and destroy cancer cells, offering a promising and less toxic alternative to traditional therapies. The company is also developing novel antibodies targeting B7-H3, a key cancer antigen and immune checkpoint, with potential applications across multiple cancer indications.
Industries
Nr. of Employees
small (1-50)
Patents
cancer vaccines; grows as an epithelial, adherent monolayer culture; does not overexpress estrogen receptors; overexpresses her2/neu; sensitive in vitro to cyclophosphamide (4HC), etoposide and taxol; resistant in vitro to carboplatin; demonstrates karyotypic abnormalities
US-7674456-B2
View Details
cancer vaccines; grows as an epithelial, adherent monolayer culture; does not overexpress estrogen receptors; overexpresses her2/neu; sensitive in vitro to cyclophosphamide (4HC), etoposide and taxol; resistant in vitro to carboplatin; demonstrates karyotypic abnormalities
US-7674456-B2
View DetailsProducts
Allogeneic GM‑CSF–secreting whole‑cell cancer vaccine
An irradiated allogeneic tumor‑derived cell line engineered to present tumor antigens and secrete immunostimulatory cytokine(s) to stimulate patient T‑cell responses; evaluated in combination with checkpoint inhibitors in metastatic cancer trials.
HLA‑matched off‑the‑shelf cell therapy platform
A platform of premanufactured cell lines engineered to express multiple HLA types to enable selection of HLA‑matched off‑the‑shelf cell therapies intended to cover large portions of patient HLA diversity.
Companion diagnostic (biomarker) test development
Development of diagnostic assays based on molecular signatures from responder versus non‑responder patients using gene expression and proteomics to guide patient stratification.
Preclinical small molecule kinase inhibitor program
Discovery and preclinical development program focused on selective kinase inhibitors with demonstrated activity in cancer and fibrotic disease models.
Computational antibody discovery and engineering program
In‑silico antibody design and molecular modeling workflows for generation and optimization of therapeutic antibodies and leads for further development into ADCs, T‑cell engagers, and immune checkpoint modulators.
Licensed biologic program (academic license)
Licensed development rights for biologic immunomodulators obtained from an academic institution under royalty and patent management arrangements.
Allogeneic GM‑CSF–secreting whole‑cell cancer vaccine
An irradiated allogeneic tumor‑derived cell line engineered to present tumor antigens and secrete immunostimulatory cytokine(s) to stimulate patient T‑cell responses; evaluated in combination with checkpoint inhibitors in metastatic cancer trials.
HLA‑matched off‑the‑shelf cell therapy platform
A platform of premanufactured cell lines engineered to express multiple HLA types to enable selection of HLA‑matched off‑the‑shelf cell therapies intended to cover large portions of patient HLA diversity.
Companion diagnostic (biomarker) test development
Development of diagnostic assays based on molecular signatures from responder versus non‑responder patients using gene expression and proteomics to guide patient stratification.
Preclinical small molecule kinase inhibitor program
Discovery and preclinical development program focused on selective kinase inhibitors with demonstrated activity in cancer and fibrotic disease models.
Computational antibody discovery and engineering program
In‑silico antibody design and molecular modeling workflows for generation and optimization of therapeutic antibodies and leads for further development into ADCs, T‑cell engagers, and immune checkpoint modulators.
Licensed biologic program (academic license)
Licensed development rights for biologic immunomodulators obtained from an academic institution under royalty and patent management arrangements.
Services
Sponsorship and operational coordination of multicenter oncology trials, including study design, site network management, and patient enrollment.
Case‑by‑case evaluation and administrative support for single‑patient IND/expanded access requests, including authorization letters and documentation requirements.
Clinical and preclinical collaboration with pharmaceutical companies and research institutions to evaluate combination regimens and investigate mechanisms of action.
Laboratory and analytic development of diagnostic tests using gene expression and proteomics to identify likely therapy responders.
Sponsorship and operational coordination of multicenter oncology trials, including study design, site network management, and patient enrollment.
Case‑by‑case evaluation and administrative support for single‑patient IND/expanded access requests, including authorization letters and documentation requirements.
Clinical and preclinical collaboration with pharmaceutical companies and research institutions to evaluate combination regimens and investigate mechanisms of action.
Laboratory and analytic development of diagnostic tests using gene expression and proteomics to identify likely therapy responders.
Expertise Areas
- Clinical trial management (Phase 1–3, randomized pivotal trials)
- Cell‑based immunotherapy development (allogeneic whole‑cell vaccines and HLA‑matched platforms)
- Biomarker discovery and companion diagnostic development
- Cell line genetic engineering for antigen presentation and cytokine secretion
Key Technologies
- Allogeneic whole‑cell immunotherapy
- HLA genotyping and matching assays
- Gene expression profiling
- Proteomics